What is the equity of NanoRepro this year?
NanoRepro has equity of 47.43 M EUR this year.
NanoRepro Equity 2024
NanoRepro Equity
47.43 M EUR
Ticker
NN6.DE
ISIN
DE0006577109
WKN
657710
In 2024, NanoRepro's equity was 47.43 M EUR, a -17.67% increase from the 57.61 M EUR equity in the previous year.
NanoRepro Aktienanalyse
What does NanoRepro do?
The Nanorepro AG was founded in 1998 in Marburg an der Lahn and has since developed into a leading company in the development and production of diagnostic rapid tests and self-tests. The company has been listed on the Frankfurt Stock Exchange since 2006 and has its headquarters in the university city of Marburg. Nanorepro's business model focuses on the production and distribution of innovative, reliable, and easy-to-use self-tests for the medical field. The company concentrates on the practical application of the tests - they should be simple, fast, and user-friendly. Nanorepro's core competence lies in the design, production, and distribution of rapid tests and self-tests for the medical field. The company relies on close cooperation with other companies and research institutions to continuously improve the tests and develop new products. Nanorepro focuses on various areas, including the manufacturing of rapid tests and self-tests for the diagnosis of infectious diseases. In addition, the company also offers tests to check pregnancy status or determine ovulation. Nanorepro's range of products also includes self-tests for the early detection of diseases such as diabetes. With its wide range of products, the company is able to address a large customer base and achieve a positive market position. One key product of Nanorepro is the early pregnancy test. This product is easy to handle and allows women to quickly and safely determine if they are pregnant or not. Nanorepro also offers an ovulation test to help women determine the timing of ovulation. Another test offered by the company is the Lyme borreliosis self-test, which allows for the detection of antibodies to Lyme borreliosis. Nanorepro also offers numerous tests for diagnosing infectious diseases. These include tests that can diagnose bacterial or viral infections such as streptococcal infections or hepatitis B and C. The tests are highly accurate and reliable, enabling quick diagnosis and treatment. Another area in which Nanorepro is expanding is the development of self-tests for the early detection of cancer. For this purpose, the company works closely with scientific and research institutions to continuously improve the tests and make them even more precise and reliable. Nanorepro places a strong emphasis on quality control and safety in the production of the tests. The products are CE-certified, ensuring high quality and safety for the user. In addition, the company has been certified according to the standards of the International Quality Management System ISO 13485, guaranteeing a high standard in the production and marketing of medical devices. Overall, Nanorepro AG has established itself as a leading company in the field of rapid tests and self-tests. With its wide range of products and constant willingness to innovate, the company is able to quickly and effectively respond to the requirements of customers and partners. The company's extensive experience in the field of medical diagnostics contributes to Nanorepro being perceived as a reliable partner in medical technology. NanoRepro ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing NanoRepro's Equity
NanoRepro's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding NanoRepro's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating NanoRepro's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
NanoRepro's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in NanoRepro’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about NanoRepro stock
What was the equity of NanoRepro compared to the previous year?
The equity of NanoRepro has increased/decreased by -17.67% decreased compared to the previous year.
What impact does a high equity have on investors of NanoRepro?
A high equity is advantageous for investors of NanoRepro as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of NanoRepro?
A low equity can be a risk for investors of NanoRepro, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of NanoRepro affect the company?
An increase in equity of NanoRepro can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of NanoRepro affect the company?
A reduction in equity of NanoRepro can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of NanoRepro?
Some factors that can affect the equity of NanoRepro include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of NanoRepro so important for investors?
The equity of NanoRepro is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can NanoRepro take to change the equity?
To change equity, NanoRepro can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does NanoRepro pay?
Over the past 12 months, NanoRepro paid a dividend of 0.5 EUR . This corresponds to a dividend yield of about 36.9 %. For the coming 12 months, NanoRepro is expected to pay a dividend of 0.5 EUR.
What is the dividend yield of NanoRepro?
The current dividend yield of NanoRepro is 36.9 %.
When does NanoRepro pay dividends?
NanoRepro pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of NanoRepro?
NanoRepro paid dividends every year for the past 1 years.
What is the dividend of NanoRepro?
For the upcoming 12 months, dividends amounting to 0.5 EUR are expected. This corresponds to a dividend yield of 36.9 %.
In which sector is NanoRepro located?
NanoRepro is assigned to the 'Health' sector.
Wann musste ich die Aktien von NanoRepro kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of NanoRepro from 6/20/2023 amounting to 0.15 EUR, you needed to have the stock in your portfolio before the ex-date on 6/16/2023.
When did NanoRepro pay the last dividend?
The last dividend was paid out on 6/20/2023.
What was the dividend of NanoRepro in the year 2023?
In the year 2023, NanoRepro distributed 0 EUR as dividends.
In which currency does NanoRepro pay out the dividend?
The dividends of NanoRepro are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The NanoRepro stock can be added to a savings plan with the following providers: ING
Andere Kennzahlen von NanoRepro
Our stock analysis for NanoRepro Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of NanoRepro Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
